With Zzzquil Efficacy Tests, P&G Highlights OTC Sleep Aid Indication
This article was originally published in The Tan Sheet & The Rose Sheet
Sleep researchers recognize many consumers look at Rx sleep disturbance treatments and OTC sleep aids as the same type of products. Still, "people are looking for options that are effective and non-habit-forming and help them get to sleep quickly," says P&G researcher Andrew Carr.
You may also be interested in...
While other national brand names compete in the OTC sleep aid tablet category, P&G’s NyQuil line extension is by far the biggest name among current players in the liquid product category, which has annual growth of nearly 80%.
With Pataday Once Daily Relief (0.2% olopatadine) and Twice Daily (0.1%), Alcon adds allergy treatment to its lineup of OTC drops indicated for dry eye and redness. “Obviously, eye allergy will become a much bigger part of the portfolio for us,” says US vision care GM Sean Clark.
UK pharma announced that in 2021 it will close its manufacturing facility in Carlisle, PA, where around 260 people are employed making the Emergen-C line. It will move the manufacturing to its Guayama, PR, facility.